Master Alliance Provisions Guide (MAPGuide)

MPP License Agreement with Pfizer re Sutezolid

  • Access to medicines | Affordable or reasonable pricing
  • Access to medicines | Equitable access

§3.3 Accessibility. MPP will require that for any Sublicensee(s) that commercializes Product(s), the Sublicensee(s) do so in a manner that facilitates its widespread availability, which commercially reasonable efforts shall include adequate manufacturing capacity, adequate supply of product meeting specifications, registration of Product(s) with applicable local and global health authorities, participation in local tenders and making available to local policy makers information regarding the Product(s). MPP will require that such Sublicensee(s) use commercially reasonable efforts to ensure that the Product(s) be made available at Affordable Pricing as quickly as possible in sufficient quantities to meet the needs of TB patients throughout the world. “Affordable Pricing” as used herein shall mean the lowest sustainable, competitive price for the Product(s) which covers the cost of raw materials, manufacturing, distribution and operational overheads, and includes a reasonable margin to help ensure the economic sustainability of the production and distribution of the Product(s).